top of page

Smoldering myeloma

Amit Garg
5 days ago
1 min read

According to the Mayo 2018 / IMWG 2/20/20 model.

Risk factor

Threshold

Serum M-protein

>2 g/dL

Involved/uninvolved free light chain ratio

>20

Bone marrow plasma cells

>20%

High risk = at least 2 of these 3 criteria

Additional adverse features include del(17p), t(4;14), gain(1q), evolving M-protein, and certain MRI abnormalities. These can refine risk assessment.

Patients meeting the 2/20/20 high-risk criteria have approximately a 40–50% risk of progression to multiple myeloma


The phase 3 AQUILA trial demonstrated with daratumumab a 51% relative reduction in the risk of progression to active multiple myeloma or death compared with active monitoring


The ASCO 2026 living guideline recommends that patients with high-risk SMM may be offered either active monitoring or daratumumab for up to 36 months, using shared decision-making.



 
 
 

Recent Posts

See All
5 Lab clues you are Iron Deficient

 1. Ferritin<30 ng/mL. Ferritin<100 ng/mL if inflammation, autoimmune diseases, cancer 2. Low transferrin saturation (TSAT) <20% suggests insufficient circulating iron availability 3. MCV <80 indicate

 
 
 

Comments


bottom of page